Scientists estimated that fewer than four emergency department visits occurred for every 1,000 patients taking semaglutide
We believe that informed patients make empowered decisions
The era of multi-pathway incretin therapy has fully arrived
Franconi F, Bennardini F, Mattana A, et al
Following rigorous quality control measures, which included the exclusion of duplicate entries, reports with incomplete demographic data (age or gender), and cases with missing temporal information, we retained 13,047 AE reports associated with concomitant GLP-1 receptor agonist and metformin therapy for final analysis
2b,c) and the carnitine synthesis inhibitor mildronate, we validated this observation in both CCNE1-driven cell lines using both olaparib and cisplatin (Fig